Expression of pS2 protein in endometrial carcinomas: Correlation with clinicopathologic features and sex steroid receptor status

International Journal of Cancer

Volumn 74, Issue 3, 1997, Pages 237-244

  Koshiyama, Masafumi ^a   Yoshida, Masumi ^a   Konishi, Mitsunaga ^a   Takemura, Maki ^a   Yura, Yasuichirou ^a   Matsushita, Katsuko ^a   Hayashi, Michiharu ^a   Tauchi, Kunihiko ^a  

^a TENRI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; SEX HORMONE;

ARTICLE; CANCER SURVIVAL; CELL DIFFERENTIATION; DRUG RECEPTOR BINDING; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENHANCER REGION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DENSITY; TARGET CELL;

EID: 0030847874     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19970620)74:3<237::aid-ijc1>3.0.co;2-%23     Document Type: Article

References (22)

1. BROWN, A.M., JELTSCH, J.M., ROBERTS, M. and CHAMBON, P., Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc. nat. Acad. Sci. (Wash.). 81, 6344-6348 (1984).
2. CROMBACH, G., INGENHORST, A., GÖHRING, U.-J., NEUMAUS, W., MÖBUS, V. and SCHAEFFER, H.-J., Expression of pS2 protein in breast cancer. Arch. Gynecol. Obstet. 353, 183-192 (1993).
3. DELIGDISH, L. and HOLINKA, F., Progesterone receptors in two groups of endometrial carcinoma. Cancer, 57, 1385-1388 (1986).
4. DETRE, S., KING, N., SALTER, J., MACLENNAN, K., MCKINNA, J.A. and DOWSETT, M., Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2. and its relation with oestrogen receptor and progesterone receptor in breast cancer. J. clin. Pathol., 47, 240-244 (1994).
5. HENRY, J.A., BENNETT, M.K., PIGGOT, N.H., LEVETT, D.L., MAY, F.E.B. and WESTLEY, R.B., Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Brit. J. Cancer, 64, 677-682 (1991).
6. HIGASHIYAMA, M., DOI, O., KODAMA, H., YOKOUCHI, H., INAJI, H., NAKAMORI, S. and TATEISHI, R., Prognostic significance of pS2 protein expression in pulmonary adenocarcinoma. Europ. J. Cancer. 30A, 792-797 (1994).
7. INAJI, H., KOYAMA, H., MOTOMURA, K., NOGUCHI, S., TSUJI, N. and WADA, A., Immunohistochemical survey of pS2 expression in intraductal lesions associated with invasive ductal carcinoma of the breast. Int. J. Cancer, 55, 883-886 (1993).
8. JELTSCH, J.M., ROBERTS, M., SCHATZ, C., GARNIER, J.M., BROWN, A.M.C. and CHAMBON, P., Structure of the human estrogen-responsive gene pS2. Nucleic Acids Res., 15, 1401-1414 (1987).
9. JENSEN, E.V., GREEN, G.L., CLOSS, L.E., DESOMBRE, E.R. and NADJI, M., Receptors reconsidered: a 20 year perspective. Rec. Progr. Hormone Res., 38, 1-40 (1982).
10. KAMBY, C., RASMUSSEN, B.B. and KRISTENSEN, B., Oestrogen receptor status of primary breast carcinomas and their metastasis. Relation to pattern of spread and survival after recurrence. Brit. J. Cancer, 60, 252-257 (1989).
11. KOSHIYAMA, M., KONISHI, I., WANG, D.P., MANDAI, M., KOMATSU, T., YAMAMOTO, S., NANBU, K., FUJIMOTO, M. and MORI, T., Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status. Virchows Arch. (A), 423, 265-271 (1993).
12. KOSHIYAMA, M., YOSHIDA, M., TAKEMURA, M., YURA, Y. MATSUSHITA, K., HAYASHI, M., TAUCHI, K., KONISHI, I. and MORI, T., Immunohistochemical analysis of distribution of estrogen receptors and progesterone receptors in the postmenopausal endometrium. Acta. Obstet. Gynecol. Scand. 75, 702-706 (1996).
13. KURMAN, R.J. and MORRIS, H.J., Endometrial carcinoma. In R.J. Kurman (ed.). Blaustein's pathology of the female genital tract (3rd ed.). pp. 338-372. Springer, Berlin (1987).
14. LESSEY, B.A., KILLAM, A.P., METZGER, D.A., HANEY, A.F., GREENE, G.L. and MCCARTY, K.S., Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J. clin. Endocrinol. Metab., 67, 334-340 (1988).
15. LUQMANI, Y.A., CAMPBELL, T., SOOMRO, S., SHOUSHA, S., RIO, M.C. and COOMBES, R.C., Immunohistochemical localization of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Brit. J. Cancer, 67, 749-753 (1993).
16. MASIAKOWSKI, P., BREATHNACH, R., BLOCK, J., GANNON, F., KRUST, A. and CHAMBON, P., Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucl. Acids Res., 10, 7895-7903 (1982).
17. NUNEZ, A.M., BERRY, M., IMLER, J.-L. and CHAMBON, P., The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens. epidermal growth factor, a tumour promoter (tpa), the c-Ha-ras oncoprotein and the c-jun protein. EMBO J., 8, 823-829 (1989).
18. PICHON, M.F. and MILGROM, E., Clinical significance of the estrogen regulated pS2 protein in mammary tumors. Crit. Rev. Oncol. Hematol., 15, 13-21 (1993).
19. RIO, M.C. BELLOCQ, J.P., GAIRARD, B., RASMUSSEN, U.B., KRUST, A., KOEHL, C., CALDEROLI, C., SCHIFF, V., RENAUD, R. and CHAMBON, P., Specific expression of the pS2 gene in sub-classes of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene erbB2. Proc. nat. Acad. SCi. (Wash.), 84, 9243-9247 (1987).
20. RUNOWICZ, C.D., NUCHTERN, I.M., BRAUSTEIN, J.D. and JONES, J.G., Heterogeneity in hormone receptor status in primary and metastatic endometrial cancer. Gynecol. Oncol., 38, 437-441 (1990).
21. WANG, D.P., KONISHI, I., KOSHIYAMA, M., MANDAI, M., NANBU, Y., ISHIKAWA, Y., MORI, T. and FUJII, S., Expression of c-erbB-2 protein and epidermal growth factor receptor in endometrial carcinomas; correlation with clinicopathologic and sex steroid receptor status. Cancer, 72, 2628-2637 (1993).
22. WYSOCKI, S.T., HÄHNEL, E., MASTERS, A., SMITH, V., MCCARTNEY, A.J. and HÄHNEL, R., Detection of pS2 messenger RNA in gynecological cancers. Cancer Res., 50, 1800-1802 (1990).